Skip to content
Open access

Cerebellar cortical amyloid deposition biases 18F-Florbetapir PET quantification with whole cerebellum as reference region.

Sep 2026 · European Journal of Nuclear Medicine and Molecular Imaging · 0 citations · 52 references
Medicine

TL;DR

Cerebellar cortical Aβ deposition raises WC reference signals and interferes with CL-based 18F-Florbetapir Aβ PET quantification, which systematically underestimates true cerebral Aβ burden.

Abstract

Objective

To investigate whether cerebellar cortical amyloid-beta (Aβ) deposition biases 18F-Florbetapir Aβ PET quantification when the whole cerebellum (WC) is used as the reference region, and to identify a stable reference region for quantification. Additionally, to establish an optimal diagnostic threshold for the detection of cerebellar cortical Aβ deposition.

Methods

This retrospective cohort study enrolled 359 Aβ-positive participants including 52 with and 307 without cerebellar cortical Aβ deposition. All participants underwent 18F-Florbetapir Aβ PET imaging, structural MRI, and cerebrospinal fluid biomarker analysis. Standardized uptake value ratio (SUVR) was derived from the standardized uptake value (SUV) by normalizing to WC, pons, and white matter (WM). Centiloid (CL) values were derived following standardized procedures. Bootstrap resampling was employed for group comparisons. Receiver operating characteristic (ROC) analysis was performed to determine the optimal SUVR threshold for identifying cerebellar cortical Aβ deposition, with validation conducted in an internal validation subset (n = 30). Two patients treated with lecanemab underwent longitudinal Aβ PET follow-up.

Results

Individuals classified as cerebellar cortical Aβ-positive exhibited significantly lower CL values than Aβ‑negative individuals (bootstrap P < 0.001). The cerebellar cortical Aβ‑positive group showed elevated SUVWC (bootstrap P = 0.012) and reduced SUVcortex (bootstrap P = 0.008), whereas SUVpons showed no significant differences between groups (bootstrap P = 0.110). SUVWM exhibited a significant intergroup difference (bootstrap P < 0.001), while SUVRWM showed no significant between-group difference (bootstrap P = 0.288). An optimal cerebellar SUVRWM threshold of 0.428 yielded excellent diagnostic performance for identifying cerebellar cortical Aβ deposition, with an area under the curve (AUC) = 0.931, sensitivity 86.5%, specificity 86.3%. Substantial agreement between quantitative and visual assessment was confirmed in the validation subset (Cohen's kappa = 0.856). In the two cerebellar cortical Aβ-positive lecanemab-treated patients, CL values decreased over time, SUVRWM showed modest alterations, while cerebellar SUVRWM remained above the 0.428 threshold throughout follow-up.

Conclusion

Cerebellar cortical Aβ deposition raises WC reference signals and interferes with CL-based 18F-Florbetapir Aβ PET quantification, which systematically underestimates true cerebral Aβ burden. The WM represents a robust reference region, and the cerebellar SUVRWM threshold of 0.428 is reliable and practical for identifying cerebellar cortical Aβ status.

Read PDF

Similar papers

Aug 2026

Regional differences in 18F-flutemetamol accumulation between amyloid-positive and -negative brains using high-resolution dedicated head PET scanner.

High-resolution dhPET revealed significantly higher SUVRs in Aβ⁺ compared with Aβ⁻ subjects in supratentorial structures, including cerebral white matter, and in cerebellar gray matter.

Yasuyuki Kojita, Kazunari Ishii, Takahiro Yamada et al. · 0 citations
Open access 2026

Brain Amyloid Burden Mapping Using MR Fingerprinting Aided by Deep Learning.

The proposed framework enables non-invasive Aβ mapping using a clinically feasible MRI protocol and may support repeated assessment for monitoring during anti-amyloid treatment.

Shohei Fujita, Y. Fushimi, Y. Otsuka et al. · 0 citations
Open access Aug 2026

A data-driven regional amyloid PET score predicts cognitive decline beyond Centiloid

Background: The Centiloid (CL) scale standardizes global amyloid PET quantification and is widely used to define amyloid positivity. As a global summary measure, however, CL may not fully reflect the regional distribution of amyloid deposition, which can carry additional prognostic information about the rate of cogniti...

T. Hirose, W. Akamatsu, T. Kato · 0 citations
Open access Sep 2026

T1 mapping in Alzheimer’s disease: a quantitative MRI study with amyloid-PET correlation

Quantitative T1 mapping (qT1) is a magnetic resonance imaging (MRI) biomarker of brain microstructural changes; however, its application in Alzheimer disease (AD) remains limited. We compared cortico-limbic qT1 values between patients with AD and healthy controls (HCs) and examined their relationship with amyloid burde...

L. Gualco, N. Montobbio, M. Losa et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.